Cargando…

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers

BACKGROUND: Asymptomatic carriers of leucine-rich repeat kinase 2 (LRRK2) gene mutations constitute an ideal population for discovering prodromal biomarkers of Parkinson’s disease (PD). In this study, we aim to identify CSF candidate risk biomarkers of PD in individuals with LRRK2 mutation carriers....

Descripción completa

Detalles Bibliográficos
Autores principales:	Majbour, Nour K., Aasly, Jan O., Hustad, Eldbjørg, Thomas, Mercy A., Vaikath, Nishant N., Elkum, Naser, van de Berg, Wilma D. J., Tokuda, Takahiko, Mollenhauer, Brit, Berendse, Henk W., El-Agnaf, Omar M. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201744/ https://www.ncbi.nlm.nih.gov/pubmed/32375873 http://dx.doi.org/10.1186/s40035-020-00192-4

Ejemplares similares

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
por: Majbour, Nour K., et al.
Publicado: (2016)

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity
por: Gupta, Vijay, et al.
Publicado: (2020)

Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers
por: Vaikath, Nishant, et al.
Publicado: (2022)

Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo
por: Sarkar, Souvarish, et al.
Publicado: (2021)

CSF or serum neurofilament light added to α‐Synuclein panel discriminates Parkinson's from controls
por: Oosterveld, Linda P., et al.
Publicado: (2019)

Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases
por: Fayyad, Muneera, et al.
Publicado: (2020)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

Clinical and Imaging Markers of Prodromal Parkinson's Disease
por: Hustad, Eldbjørg, et al.
Publicado: (2020)

α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers
por: Gorostidi, Ana, et al.
Publicado: (2012)

Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies
por: Gupta, Vijay, et al.
Publicado: (2020)

Acetylated α-Tubulin and α-Synuclein: Physiological Interplay and Contribution to α-Synuclein Oligomerization
por: Calogero, Alessandra Maria, et al.
Publicado: (2023)

The Role of α-Synuclein and LRRK2 in Tau Phosphorylation
por: Kawakami, Fumitaka, et al.
Publicado: (2015)

Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays
por: Anagnostou, Dimitrios, et al.
Publicado: (2023)

α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity
por: Ghanem, Simona S., et al.
Publicado: (2022)

RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
por: Outeiro, Tiago Fleming, et al.
Publicado: (2008)

LRRK2 G2019S promotes astrocytic inflammation induced by oligomeric α-synuclein through NF-κB pathway
por: He, Kai-Jie, et al.
Publicado: (2023)

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid(42) and DJ-1 in Human Cerebrospinal Fluid
por: Kruse, Niels, et al.
Publicado: (2016)

Dopamine-Mediated Oxidation of Methionine 127 in α-Synuclein Causes Cytotoxicity and Oligomerization of α-Synuclein
por: Nakaso, Kazuhiro, et al.
Publicado: (2013)

Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson’s disease patients
por: Kang, Wenyan, et al.
Publicado: (2016)

The accuracy of the clinical diagnosis of Parkinson disease. The HUNT study
por: Hustad, Eldbjørg, et al.
Publicado: (2018)

Increased Mortality in Young-Onset Parkinson’s Disease
por: Hustad, Eldbjørg, et al.
Publicado: (2021)

Membrane Permeabilization by Oligomeric α-Synuclein: In Search of the Mechanism
por: van Rooijen, Bart D., et al.
Publicado: (2010)

Seeking a Mechanism for the Toxicity of Oligomeric α-Synuclein
por: Roberts, Hazel L., et al.
Publicado: (2015)

Oligomerization by co-assembly of β-amyloid and α-synuclein
por: Kim, Jin Ryoun
Publicado: (2023)

Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study
por: Donadio, V., et al.
Publicado: (2018)

LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?
por: O’Hara, Darren M., et al.
Publicado: (2020)

Decrease in Plasma Levels of α-Synuclein Is Evident in Patients with Parkinson’s Disease after Elimination of Heterophilic Antibody Interference
por: Ishii, Ryotaro, et al.
Publicado: (2015)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Formation of Toxic Oligomeric α-Synuclein Species in Living Cells
por: Outeiro, Tiago Fleming, et al.
Publicado: (2008)

α-synuclein interacts with SOD1 and promotes its oligomerization
por: Helferich, Anika M., et al.
Publicado: (2015)

Identification of Synaptosomal Proteins Binding to Monomeric and Oligomeric α-Synuclein
por: Betzer, Cristine, et al.
Publicado: (2015)

Probing the Origin of the Toxicity of Oligomeric Aggregates of α-Synuclein with Antibodies
por: Cascella, Roberta, et al.
Publicado: (2019)

LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models
por: Guerreiro, Patrícia Silva, et al.
Publicado: (2012)

A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations
por: Mollenhauer, Brit, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uupj5ugengoj98t0sgqgf74sno